



# Multi-Stakeholder Recommendations for Action Against Antimicrobial Resistance: a Public Consultation

Zilke Claessens<sup>1\*</sup>, Elise Schoefs<sup>1\*</sup>, Io Wens<sup>1</sup>, Isabelle Huys<sup>1</sup>

Contact: zilke.claessens@kuleuven.be

<sup>1</sup>Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven (Belgium)

### BACKGROUND AND OBJECTIVES

**antimicrobial resistance (AMR)**

Need for  
(i) Facilitating the introduction of novel antimicrobials  
(ii) Responsible use of existing antibiotics

Actions included in the proposal for the reform of the EU pharmaceutical legislation

**Objectives:**  
Assess stakeholder recommendations based on public consultation feedback informing the legislation

### METHODS


Public consultation (Survey) by European Commission

- Multiple-choice questions (N=10)
- Open-end questions (N=5)

Descriptive analysis      Qualitative thematic framework analysis

**Sub-group analysis (N=478)**

End-users N=90 (19%)	HCP N=82 (17%)	Industry N=172 (36%)
Public Body N=36 (7,5%)	Research N=33 (7%)	Other N=66 (13,5%)



### INCENTIVES TO STIMULATE R&D IN ANTIMICROBIALS

	Public Body	Industry	HCP	End-users	Researcher
Transferable exclusivity voucher		✓	✗	✗	✗
Additional AMR specific regulatory flexibilities, such as priority review and fast-track programs	✓	✓			✓
Decreased regulatory fees		✓	✓	✓	
Development of EU priority pathogen list		✓	✓		

### PRICING MECHANISMS

	Public Body	Industry	HCP	End-users	Researcher
Subscription payment model		✓			✓
European responsibility e.g. via joint procurement practice		✓			✓

### RESPONSIBLE USE

	Public Body	Industry	HCP	End-users	Researcher
Mandatory training for HCPs and public health education	✓	✓		✓	
Ban over-the-counter antimicrobials				✓	✓
Restricted regulation for non-human use of antibiotics	✓	✓	✓	✓	
Monitor prescription behavior and resistance				✓	✓

### CONCLUSION

**1**

The proposal for the new pharmaceutical legislation receives a lot of reaction by stakeholders, this nuanced analysis of the public consultation can enhance understanding

**2**

Not all included actions (i.e. transferable exclusivity voucher) were supported by all stakeholder groups

**3**

Additional actions could be included to further enhance innovation (i.e. reduced regulatory fees, a priority pathogens list) and responsible use (i.e. more restricted regulation)

### ACKNOWLEDGEMENTS

ZC is SB PhD fellow at FWO - 1S52125N

### LIST OF ABBREVIATIONS

AMR: antimicrobial resistance, EU: European Union, HCP: Health care practitioner